The rise of copyright’s blockbuster initially sparked a period of growth for major pharmaceutical companies, however recent shifts present a complicated scenario for shareholders. Off-patent versions are eating into profits, and ongoing patent challenges add more risk to the equation. While certain companies could still gain from related offering